Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

NCT05272826 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Iberdomide
DRUG: Bortezomib
DRUG: Dexamethasone
DRUG: Isatuximab

Sponsor

Canadian Myeloma Research Group